Skin permeation of buprenorphine and its ester prodrugs from lipid nanoparticles: Lipid emulsion, nanostructured lipid carriers and solid lipid nanoparticles

Journal of Microencapsulation

Volumn 26, Issue 8, 2009, Pages 734-747

  Wang, Jhi Joung ^a   Liu, Kuo Sheng ^b   Sung, K C ^b   Tsai, Chia Yin ^c   Fang, Jia You ^c  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Buprenorphine; Ester prodrug; Lipid emulsion; Nanostructured lipid carriers; Skin permeation; Solid lipid nanoparticles

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE ENANTHATE; BUPRENORPHINE PROPIONATE; BUPRENORPHINE VALERATE; DRUG CARRIER; EMULSIFYING AGENT; GLYCEROL OLEATE; GLYCEROL PALMITOSTEARATE; GLYCEROL PALMITOSTEARATE PLUS SQUALENE; LIPID EMULSION; MORPHINE DERIVATIVE; NANOMATERIAL; NANOPARTICLE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPON 80H; PRODRUG; SOLID LIPID NANOPARTICLE; SQUALENE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; IN VITRO STUDY; LIPOPHILICITY; MOUSE; NONHUMAN; PARTICLE SIZE; PLASMA; SKIN; SKIN PERMEABILITY; SOYBEAN;

ANIMALS; BUPRENORPHINE; EMULSIONS; LIPIDS; MICE; NANOPARTICLES; NARCOTICS; PERMEABILITY; PRODRUGS; SKIN;

EID: 70449369890     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652040902746679     Document Type: Article

References (39)

1. Bose S, Ravis WR, Lin YJ, Zhang L, Hofmann GA, Banga AK. 2001. Electrically-assisted transdermal delivery of buprenorphine. J Contr Rel 73:197-203.
2. Bunjes H, Koch MHJ, Westesen K. 2003. Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J Pharm Sci 92:1509-1520.
3. Chen H, Chang X, Du D, Liu W, Liu J, Weng T, et al. 2006. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Contr Rel 110:296-306.
4. Chin LS, Huang KL, Liu KS, Chu CC, Tzeng JI, Ho ST, et al. 2005. An esterification method for synthesizing prodrugs of buprenorphine. Acta Anaesthesiol Taiwanica 43:223-229.
5. Evans HC, Easthope SE. 2003. Transdermal buprenorphine. Drugs 63:1999-2010.
6. Fang JY, Hung CF, Hwang TL, Huang YL. 2005. Physicochemical characteristics and in vivo deposition of liposome-encapsulated tea catechins by topical and intratumor administrations. J Drug Target 13:19-27.
7. Fang JY, Hwang TL, Huang YL. 2006. Liposomes as vehicles for enhancing drug delivery via skin routes. Curr Nanosci 2:55-70.
8. Fang JY, Leu YL. 2006. Prodrug strategy for enhancing drug delivery via skin. Curr Drug Discov Technol 3:211-224.
9. Hammell DC, Stolarczyk EI, Klausner M, Hamad MO, Crooks PA, Stinchcomb AL. 2005. Bioconversion of naltrexone and its 3-O-alkylester prodrugs in a human skin equivalent. J Pharm Sci 94:828-836.
10. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. 2006. Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm 314:83-89.
11. Imoto H, Zhou Z, Stinchcomb AL, Flynn GL. 1996. Transdermal prodrug concepts: Permeation of buprenorphine and its alkyl esters through hairless mouse skin and influence of vehicles. Biol Pharm Bull 19:263-267.
12. Jenning V, Thunemann AF, Gohla SH. 2000. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 199:167-177. (Pubitemid 30236188)
13. Juntunen J, Majumdar S, Sloan KB. 2008. The effect of water solubility of solutes on their flux through human skin in vitro: A prodrug database integrated into the extended Flynn database. Int J Pharm 351:92-103.
14. Kuchler S, Radowski MR, Blaschke T, Dathe M, Plendl J, Haag R, et al. 2009. Nanoparticles for skin penetration enhancement-a comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles.Eur J Pharm Biopharm, in press.
15. Kawaguchi T, Tsugane A, Higashide K, Endoh H, Hasegawa T, Kanno H, et al. 1992. Control of drug release with a combination of prodrug and polymer matrix: Antitumor activity and release profiles of 2. J Pharm Sci 81:508-512.
16. Kleppner SR, Patel R, McDonough J, Costantini LC. 2006. In-vitro and in-vivo characterization of a buprenorphine delivery system. J Pharm Pharmacol 58:295-302.
17. Kogan A, Garti N. 2006. Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interface Sci 123-126:369-385.
18. Lipp R, Laurent H, Gunther C, Riedl J, Esperling P, Tauber U. 1998. Prodrugs of gestodene for matrix-type transdermal drug delivery systems. Pharm Res 15:1419-1424.
19. Liu KS, Tzeng JI, Chen YW, Huang KL, Kuei CH, Wang JJ. 2006. Novel depots of buprenorphine prodrugs have a long-acting antinociceptive effect. Anesth Analg 102:1445-1451.
20. Lombardi Borgia S, Regehly M, Sivaramakrishnan R, Mehnert W, Korting HC, Danker K, et al. 2005. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Contr Rel 110:151-163. Musssller RH. 2007. Lipid nanoparticles: Recent advances. Adv Drug Deliv Rev 59:522-530. Mu ller RH, Mader K, Gohla S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 50:161-177. Mu ller RH, Radtke M, Wissing SA. 2002. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54:S131-S155.
21. Montenegro L, Carbone C, Maniscalco C, Lambusta D, Nicolosi G, Ventura CA, et al. 2007. In vitro evaluation of quercetin-3-O-acyl esters as topical prodrugs. Int J Pharm 336:257-262.
22. Ostacolo C, Marra F, Laneri S, Sacchi A, Nicoli S, Padula C, et al. 2004. Tocopherol pro-vitamins: Synthesis, hydrolysis and accumulation in rabbit ear skin. J Contr Rel 99:403-413.
23. Park I, Kim D, Song J, In CH, Jeong SW, Lee SH, et al. 2008. BupredermTM, a new transdermal delivery system of buprenorphine: Pharmacokinetic, efficacy and skin irritancy studies. Pharm Res 25:1052-1062.
24. Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C, et al. 2008. Lipid nanoparticles for prolonged topical delivery: An in vitro and in vivo investigation. Int J Pharm 357:295-304.
25. Rautio J, Nevalainen T, Taipale H, Vepsalanen J, Gynther J, Laine K, et al. 2000. Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation. Eur J Pharm Sci 11:157-163.
26. Schmid-Grendelmeier P, Pokorny R, Gasser UE, Richarz U. 2006. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers. Curr Med Res Opin 22:501-509.
27. Sorge J, Sittl R. 2004. Transdermal buprenorphine in the treatment of chronic pain: Results of a phase III, multicenter, randomized, doubleblind, placebo-controlled study. Clin Ther 26:1808-1820.
28. Souto EB, Almeida AJ, Mus ller RH. 2007. Lipid nanoparticles (SLN-, NLC-) for cutaneous drug delivery: Structure, protection and skin effects. J Biomed Nanotechnol 3:317-331.
29. Stinchcomb AL, Dua R, Paliwal A, Woodard RW, Flynn GL. 1995. A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharm Res 12:1526-1529.
30. Stinchcomb AL, Paliwal A, Dua R, Imoto H, Woodard RW, Flynn GL. 1996. Permeation of buprenorphine and its 3-alkyl-ester prodrugs through human skin. Pharm Res 13:1519-1523.
31. Suppasansatorn P, Wang G, Conway BR, Wang W, Wang Y. 2006. Skin delivery potency and antitumor activities of temozolomide ester prodrugs. Cancer Lett 244:42-52.
32. Swenson J, Olgun S, Radjavi A, Kaur T, Reilly CM. 2007. Clinical efficacy of buprenorphine to minimize distress in MRL/lpr mice. Eur J Pharmacol 567:67-76.
33. Thomas JD, Sloan KB. 2008. In vitro evaluation of alkylcarbonyloxymethyl (ACOM) ethers as novel prodrugs of phenols for topical delivery: ACOM prodrugs of acetaminophen. Int J Pharm 346:80-88.
34. Trotta M, Peira E, Carlotti ME, Gallarate M. 2004. Deformable liposomes for dermal administration of methotrexate. Int J Pharm 270:119-125.
35. Valjakka-Koskela R, Kirjavainen M, Monkkonen J, Urtti A, Kiesvaara J. 1998. Enhancement of percutaneous absorption of naproxen by phospholipids. Int J Pharm 175:225-230.
36. Venkateswarlu V, Manjunath K. 2004. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Contr Rel 95:627-638.
37. Wang JJ, Sung KC, Hu OYP, Yeh CH, Fang JY. 2006. Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs. J Contr Rel 115:140-149.
38. Wang JJ, Sung KC, Yeh CH, Fang JY. 2008. The delivery and antinociceptive effects of morphine and its ester prodrugs from lipid emulsions. Int J Pharm 353:95-104.
39. Wilding R, Davis SS, Rimoy GH, Rubin P, Kurihara-Bergstrom T, Tipnis V, et al. 1996. Pharmacokinetic evaluation of transdermal buprenorphine in man. Int J Pharm 132:81-87.